Generic placeholder image

Recent Patents on Endocrine, Metabolic & Immune Drug Discovery


ISSN (Print): 1872-2148
ISSN (Online): 2212-3334

Targeting Chemokine (C-X-C motif) Receptor 3 in Thyroid Autoimmunity

Author(s): Poupak Fallahi, Silvia Martina Ferrari, Alda Corrado, Dilia Giuggioli, Clodoveo Ferri and Alessandro Antonelli

Volume 8 , Issue 2 , 2014

Page: [95 - 101] Pages: 7

DOI: 10.2174/1872214808666140623114315

Price: $65


The C-X-C chemokine receptor (CXCR)3 and its chemokines (CXCL9, CXCL10, CXCL11) are involved in the pathogenesis of autoimmune thyroiditis (AT), Graves’ disease (GD) and Graves’ Ophthalmopathy (GO). Under the influence of interferon(IFN)γ, the IFNγ-induced protein 10 (IP-10/CXCL10) is secreted by thyrocytes, orbital fibroblasts and preadipocytes. In tissue, Th1 lymphocytes are recruited; hence IFNγ is enhanced, which stimulates CXCL10 secretion reiterating the autoimmune process. The presence of elevated levels of CXCL10 in peripheral liquids is considered a marker of Th1 orientated immune response. High levels of circulating CXCL10 (sCXCL10) have been shown in patients with AT, overall with hypothyroidism. In GD and GO patients high sCXCL10 have been shown particularly in the active disease. A modulatory role of peroxisome proliferator-activated receptor (PPAR)γ or - α agonists on CXCR3 chemokines in AT, GD and GO and the immuno-modulatory effect of methimazole on CXCR3 chemokines in GD have been shown. Further studies are ongoing to explore the use of new molecules that act as antagonists of CXCR3, or block CXCL10, in autoimmune disorders, and many interesting patents have been recently applied.

Keywords: CXCL9, CXCL10, CXCL11, CXCR3, Graves’ disease, thyroid autoimmunity, thyroid autoantibodies, thyroiditis.

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy